About this trial
The purpose of this study is to test whether giving treatment before surgery helps babies who are newly diagnosed with Infant-Type Hemispheric Glioma (IHG) have safer and better surgery results.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Patient with presumptive or suspected (new) diagnosis of Infant-Type Hemispheric Glioma (IHG)
Patient age at diagnosis is from birth to ≤ 60 months
Patient has MRI/CT scan imaging of a supra-tentorial, hemispheric tumor avail-able for review before screening consent.
Patient is willing to undergo a biopsy procedure to confirm tissue diagnosis.
Disqualifiers
Age > 60 months
Any prior cancer-directed therapy
Organ Dysfunction, or a medical condition that, in the principal investigator's judgment, could compromise their ability to tolerate or absorb protocol therapy or would interfere with study procedures and results.
Trial design
Parallel
Treatments tested in this trial
Alectinib
DrugBy mouth, nasogastric, or gastronomy/stomach tube, Day 1-28
Entrectinib
DrugBy mouth, nasogastric, or gastronomy/stomach tube, Day 1-28
Surgery
Procedure/SurgeryPrimary surgery (Strata A, B, and C) post Neoadjuvant therapy with a goal of attaining gross total (GTR) or near total resection (NTR) of the tumor.
Cyclophosphamide
DrugIV (intravenous) day 1
Etoposide
DrugIV (intravenous) days 1 and 2
Carboplatin
DrugIV (intravenous) day 2
Filgrastim
Biological/VaccineSubcutaneous (under the skin) or IV (intravenous) day 3
Pegfilgrastim
Biological/VaccineSubcutaneous (under the skin) day 3
Surgery
Procedure/SurgeryPrimary surgery (Strata A, B, and C) post Neoadjuvant therapy with a goal of attaining gross total (GTR) or near total resection (NTR) of the tumor.
Treatment groups
Trial outcomes
Primary outcomes
Rate of Complete Tumor Response (CTR) among patients in Strata A, B, and C
The proportion of patients whose extent of tumor resection meets criteria for gross total / near total resection (GTR/NTR) after neoadjuvant therapy and surgery.
Rate of safe surgical resection among patients in Strata A, B, and C
Proportion of patients whose surgery is completed without clinically significant intra-operative blood loss/hemorrhage. Success for this outcome measure will include surgery without any of the following: (i) Initiation of massive transfusion protocol- i.e., requiring more than one volume (80ml/Kg) of transfusion over a period of 24 hours (ii) Hemorrhage leading to cessation of surgery (iii) Hemorrhagic complications leading to second neurosurgery within 72 hours of the first surgery.
Secondary outcomes
Event free survival (EFS)
EFS is defined as time from enrollment for treatment (including bridge therapy) until progression, subsequent malignancy or death for any reason or until last follow-up, whichever is earlier.
Overall survival (OS)
OS is defined as time from enrollment for treatment (including bridge therapy) until death for any reason or until last follow-up, whichever is earlier.
Change in neurodevelopment and cognitive performance pre- and post-primary surgery in infants with newly diagnosed IHG treated with molecularly directed neoadjuvant treatment: BSID-4
Change in neurodevelopment and cognitive performance pre- and post-primary surgery in infants with newly diagnosed IHG treated with molecularly directed neoadjuvant treatment: NIH Baby Toolbox
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
St. Jude Children's Research Hospital
Lead sponsor
St. Baldrick's Foundation
Collaborator
Genentech, Inc.
Collaborator
This trial is not recruiting at the moment. You can still explore other options: